• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, September 13, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

NIH selects Cardax compound for important anti-aging research program

Bioengineer by Bioengineer
June 18, 2017
in Health
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

The University of Hawaii (UH) John A. Burns School of Medicine (JABSOM) and Cardax, Inc. (Cardax), a Hawaii based life sciences company, announced today that the National Institute on Aging (NIA), part of the National Institutes of Health (NIH), has selected the proprietary Cardax astaxanthin compound CDX-085 for its anti-aging Interventions Testing Program (ITP).

"Getting into the Interventions Testing Program with the National Institute on Aging is a game-changer," said Dr. Bradley Willcox, M.D., Professor and Director of Research at the Department of Geriatric Medicine at JABSOM. "It puts CDX-085, Cardax's proprietary astaxanthin compound, into a very elite club of compounds that have the potential to become true anti-aging therapies."

In March of this year, JABSOM and Cardax jointly announced that CDX-085 showed the ability to significantly activate the FOXO3 gene in mice, which plays a proven role in longevity.

"Out of all the compounds they could have chosen, they chose ours," said David G. Watumull, Cardax CEO. "It's an important validation of the work that we've done here in Hawaii."

The NIA ranked the proposal submitted by UH faculty members Dr. Willcox and Richard Allsopp, Ph.D. a "high priority," its highest ranking. Dr. Willcox is Principal Investigator of the NIH-funded Kuakini Hawaii LIFESPAN and HEALTHSPAN Studies and Cardax Scientific Advisory Board member. Dr. Allsopp is an Associate Professor at the Institute for Biogenesis Research at JABSOM.

"The information we get from the ITP is going to be quite significant and should greatly enhance our knowledge of how astaxanthin/CDX-085 affects aging," added Dr. Allsopp.

The NIA funds the rigorous and extensive studies included in the ITP, which are conducted at several labs across the country.

The ITP will build upon the research by JABSOM and Cardax demonstrating the ability of CDX-085 to activate the important anti-aging gene FOXO3 in mice. CDX-085, like the Company's first generation dietary supplement, ZanthoSyn™, delivers astaxanthin to the bloodstream with optimal absorption and purity.

###

Media Contact

Tina Shelton
[email protected]
808-554-2586
@UHCancerCenter

http://www.uhcancercenter.org/

https://spaces.hightail.com/space/X6kwX4aVjC

############

Story Source: Materials provided by Scienmag

Share12Tweet7Share2ShareShareShare1

Related Posts

Interpretable Deep Learning for Anticancer Peptide Prediction

September 13, 2025

Navigating Shadows: Treating Anorexia and C-PTSD

September 13, 2025

Preoperative BMI Influences Outcomes in Infective Endocarditis

September 13, 2025

Adverse Events in Asian Adults on Brivaracetam

September 13, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    153 shares
    Share 61 Tweet 38
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    116 shares
    Share 46 Tweet 29
  • Physicists Develop Visible Time Crystal for the First Time

    65 shares
    Share 26 Tweet 16
  • A Laser-Free Alternative to LASIK: Exploring New Vision Correction Methods

    49 shares
    Share 20 Tweet 12

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Boosting Xanthan Gum Production with Essential Oil By-products

Groundwater Pesticide Contamination: Challenges and Solutions

FBXW11 Ubiquitinates YB1, Suppressing Hepatocarcinoma Growth

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.